{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:29:50Z","timestamp":1772861390096,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T00:00:00Z","timestamp":1312243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s11096-011-9541-y","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T11:59:52Z","timestamp":1312199992000},"page":"806-814","source":"Crossref","is-referenced-by-count":29,"title":["Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case"],"prefix":"10.1007","volume":"33","author":[{"given":"Carla","family":"Meyer-Massetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Vaerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra E.","family":"R\u00e4tz Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph R.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Joseph","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"9541_CR1","unstructured":"Food and Drug Administration. FDA alert: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). This alert highlights revisions to the labeling for haloperidol. 2007. Available from: www.fda.gov . Cited 30 Jun 2010."},{"key":"9541_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.156.1.1","volume":"156","author":"Practice guideline for the treatment of patients with delirium","year":"1999","unstructured":"Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry. 1999;156:1\u201320.","journal-title":"Am J Psychiatry."},{"key":"9541_CR3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00003246-200201000-00020","volume":"30","author":"J Jacobi","year":"2002","unstructured":"Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119\u201341.","journal-title":"Crit Care Med."},{"key":"9541_CR4","unstructured":"Haldo lV injection (for immediate release) Package Insert. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc.; 2005;rev. 05.2007."},{"key":"9541_CR5","unstructured":"Documed AG Basel. Arzneimittel-Kompendium der Schweiz. 2010. No date. Available from: www.kompendium.ch . Cited 12 Feb 2010."},{"key":"9541_CR6","unstructured":"CPS Compendium of Pharmaceuticals and Specialties, the Canadian drug reference for health professionals. The Canadian Pharmacists\u2019 Association; 2007."},{"key":"9541_CR7","unstructured":"VIDAL\u2014l\u2019information sur les produits de sante. 2008. No date. Available from: www.vidal.fr . Cited 12 Feb 2010."},{"key":"9541_CR8","unstructured":"Rote Liste Service GmbH Frankfurt am Main. Rote Liste Deutschland. 2008. No date. Available from: www.rote-liste.de . Cited 12 Feb 2010."},{"key":"9541_CR9","unstructured":"BNF British National Formulary 2007, compendium of pharmaceuticals and specialties of the UK. 2007. Available from: www.bnf.org . Cited 28 Feb 2009."},{"key":"9541_CR10","unstructured":"Haldol iniettabile\u2014ufficiale monografia italiana. 2009. Availble from: www.informatorefarmaceutico.it . Cited 28 Feb 2009."},{"key":"9541_CR11","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/jhm.691","volume":"5","author":"C Meyer-Massetti","year":"2010","unstructured":"Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5:E8\u201316.","journal-title":"J Hosp Med."},{"key":"9541_CR12","unstructured":"Arzneimittelkommission der Deutschen \u00c4rzteschaft Akd\u00c4. Information \u00fcber die \u00c4nderung der bisher empfohlenen Applikationswege von Haldol-Janssen Injektionswege. Drug safety mail [098]. 2010. Available from: http:\/\/www.akdae.de\/Arzneimittelsicherheit\/DSM\/Archiv\/2010-098.html . Cited 7 May 2010."},{"key":"9541_CR13","first-page":"1180","volume":"28","author":"M Lindquist","year":"2001","unstructured":"Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol. 2001;28:1180\u20137.","journal-title":"J Rheumatol."},{"key":"9541_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2125.1997.00652.x","volume":"44","author":"AC Egberts","year":"1997","unstructured":"Egberts AC, Meyboom RH, De Koning FH, Bakker A, Leufkens HG. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol. 1997;44:277\u201381.","journal-title":"Br J Clin Pharmacol."},{"key":"9541_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Puijenbroek van","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"9541_CR16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","volume":"34","author":"Y Ozeki","year":"2010","unstructured":"Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:401\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"9541_CR17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00134-003-2117-0","volume":"30","author":"YK Skrobik","year":"2004","unstructured":"Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004;30:444\u20139.","journal-title":"Intensive Care Med."},{"key":"9541_CR18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0033-3182(98)71301-5","volume":"39","author":"A Sipahimalani","year":"1998","unstructured":"Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics. 1998;39:422\u201330.","journal-title":"Psychosomatics."},{"key":"9541_CR19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/PCC.v02n0103","volume":"2","author":"TL Schwartz","year":"2000","unstructured":"Schwartz TL, Masand PS. Treatment of Delirium With Quetiapine. Prim Care Companion J Clin Psychiatry. 2000;2:10\u20132.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"issue":"Suppl 2","key":"9541_CR20","first-page":"35","volume":"62","author":"J Czekalla","year":"2001","unstructured":"Czekalla J, Kollack-Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry. 2001;62(Suppl 2):35\u201340.","journal-title":"J Clin Psychiatry."},{"key":"9541_CR21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00004714-200102000-00003","volume":"21","author":"MW Agelink","year":"2001","unstructured":"Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001;21:8\u201313.","journal-title":"J Clin Psychopharmacol."},{"key":"9541_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/appi.ajp.157.2.304-a","volume":"157","author":"RF Bosch","year":"2000","unstructured":"Bosch RF, Baumbach A, Bitzer M, Erley CM. Intoxication with olanzapine. Am J Psychiatry. 2000;157:304\u20135.","journal-title":"Am J Psychiatry."},{"key":"9541_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1192\/bjp.179.2.167","volume":"179","author":"H Cohen","year":"2001","unstructured":"Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry. 2001;179:167\u201371.","journal-title":"Br J Psychiatry."},{"key":"9541_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/apt.8.1.49","volume":"8","author":"WP Bouman","year":"2002","unstructured":"Bouman WP, Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Adv Psychiatr Treat. 2002;8:49\u201358.","journal-title":"Adv Psychiatr Treat."},{"key":"9541_CR25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1592\/phco.27.4.588","volume":"27","author":"RS Rea","year":"2007","unstructured":"Rea RS, Battistone S, Fong JJ, Devlin JW. Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy. 2007;27:588\u201394.","journal-title":"Pharmacotherapy."},{"key":"9541_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.42.4.347","volume":"42","author":"R Torres","year":"2001","unstructured":"Torres R, Mittal D, Kennedy R. Use of quetiapine in delirium: case reports. Psychosomatics. 2001;42:347\u20139.","journal-title":"Psychosomatics."},{"key":"9541_CR27","unstructured":"ARIZONA CERT, Arizona Center for Education and Research on Therapeutics. No date. Available from: www.azcert.org . Cited 18 June 2011."},{"key":"9541_CR28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0447.1997.tb09642.x","volume":"95","author":"PG Janicak","year":"1997","unstructured":"Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr Scand. 1997;95:343\u201350.","journal-title":"Acta Psychiatr Scand."},{"key":"9541_CR29","unstructured":"US Food and Drug Administration. FDA Public Health Advisory: deaths with antipsychotics in elderly patients with behavioural disturbances. 2005. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/UCM053171 . Cited 22 Feb 2010."},{"key":"9541_CR30","unstructured":"US Food and Drug Administration. FDA requests boxed warnings on older class of antipsychotic drugs. FDA news release. 2008. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2008\/ucm116912.htm . Cited 22 Feb 2010."},{"key":"9541_CR31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"9541_CR32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ageing\/afg061","volume":"32","author":"W Neil","year":"2003","unstructured":"Neil W, Curran S, Wattis J. Antipsychotic prescribing in older people. Age Ageing. 2003;32:475\u201383.","journal-title":"Age Ageing."},{"key":"9541_CR33","first-page":"282","volume":"82","author":"D Zeltser","year":"2003","unstructured":"Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282\u201390.","journal-title":"Medicine (Baltimore)."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-011-9541-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-011-9541-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-011-9541-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:54:33Z","timestamp":1559354073000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-011-9541-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["9541"],"URL":"https:\/\/doi.org\/10.1007\/s11096-011-9541-y","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,2]]}}}